Predicine

Join us at the Predicine Liquid Biopsy Summit 2025 – Shanghai, part of Predicine’s Global 10th Anniversary Celebration Series, commemorating a decade of innovation in liquid biopsy and precision medicine.

• Date: October 25, 2025 (Saturday)

• Time: 9:00 AM - 3:00 PM (GMT +8)

• Venue: JW Marriott Hotel Shanghai, Tomorrow Square, Shanghai, China

Join peers from industry, academia, and clinical practice to explore the latest advances in liquid biopsy and precision oncology - and celebrate a decade of innovation and quality at Predicine.

Program highlights:

• Targeted Therapy: Liquid Biopsy for Drug Development - RAS & Beyond

• ADCs & Immunotherapy: Liquid Biopsy for Drug Development - PD1/VEGF & Beyond

• From China to the World: Biomarker-Enabled Acceleration of Global Clinical Trial

RSVP HERE: https://www.eventbrite.com/e/predicine-liquid-biopsy-summit-shanghai-tickets-1805698315269?aff=oddtdtcreator

A confirmation email will be sent based on first come first serve basis due to limited space.

We look forward to welcoming you to the event.

Visit Predicine at Booth #6 — Multi-omic liquid biopsy for RAS drug development

Don’t miss our Sept 17th presentation addressing ultra-deep genomic sequencing, methylation, and cfRNA profiling for RAS-targeted drug development.

At the 7th RAS-Targeted Drug Development Summit, Predicine will share its integrated, multi-omic profiling data in liquid biopsy to enable faster, data-driven decisions in RAS-targeted clinical development.

Presentation

• Wednesday, September 17, 2025 | 1:50 PM ET

• Integrated Liquid Biopsy Profiling to Accelerate RAS Clinical Drug Development

What we’ll cover

• Genomic ultra-deep profiling using a blood-informed minimal residual disease (MRD) approach to support RAS-targeted clinical trials and enable data-driven go/no-go decision-making

• Epigenomic methylation profiling for enhanced detection of therapy response dynamics and resistance mechanisms

• Tissue and blood-based RNA profiling to advance next-generation RAS drug development through transcriptomic insights


Meet us on-site

• Booth #6

• Schedule a 1:1 with our team: [email protected]?ismsaljsauthenabled=true" rel="ugc" target="_blank">https://outlook.office.com/book/[email protected]?ismsaljsauthenabled=true

Join Predicine at WCLC 2025 at booth #105!

📑 Featured Poster: Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated With HER2 ADC: Preliminary Results From the RESOLUTION Trial

This study demonstrates how ctDNA-guided monitoring can enable early detection of disease progression and real-time insights into treatment response in HER2+ NSCLC.

Learn more here: https://cattendee.abstractsonline.com/meeting/21151/Session/163

📍 At WCLC 2025, Predicine is showcasing how its’ comprehensive & ultra-sensitive liquid biopsy solutions are uniquely positioned to address emerging priorities in the lung cancer field such as:

• Patient enrollment – recruiting additional patients for KRAS, MTAP, MET, EGFR, HER2, ALK, ROS1 using an ultra-sensitive blood assay at the MRD level

• MRD Detection & Longitudinal Monitoring – blood-informed MRD approach, enabling earlier and actionable insights into recurrence and therapy response with high sensitivity for targeted therapy and PD1/VEGF

• Resistance Mechanisms – tracking biomarkers at an unprecedented MRD level in blood to guide next-line therapies

• Broad Assay Coverage – integrating ctDNA/cfRNA, and genomics, epigenomics, and transcriptomics to capture tumor heterogeneity and novel targets

• Global Scalability – seamless support for pharma clinical trials with fast turnaround, reproducibility, and harmonized testing solutions including US, EU, China, JP, and LATAM

🔗 Schedule a meeting with our team: https://lnkd.in/grdVE6B8

On Day 5 of , visit Predicine at Booth #2643 to see how end-to-end liquid biopsy revolutionizing oncology trials is—from global sample logistics to ultra-sensitive molecular insights.

Highlights

• One-stop Global Sample Management:
PredicineDIRECT™ delivers a “from sample to result” workflow with fast turnaround time, cost-effective management, and accurate specimen tracking by combining worldwide collection, real-time SNP barcoding, and tumor-fraction monitoring.

• Prostate Cancer Detection:
PredicineSCORE™ delivers non-invasive early cancer detection with high sensitivity and accuracy by leveraging AI-driven integration of cfDNA fragmentomic characteristics, including regional coverage, end-motif signatures, and EM-refined copy-number burden.

Stop by Booth #2643 to learn how Predicine’s AAA solutions are accelerating biomarker discovery, enhancing trial efficiency, and advancing precision oncology.